PML - Horizon reports new analysis from late-stage Uplinza study for NMOSD in medical journal

Horizon Therapeutics (NASDAQ:HZNP) announces the publication of a post-hoc analysis from the N-MOmentum phase 2/3 trial of UPLIZNA, which highlights a sustained effect on attack risk with no new safety signals in people with Neuromyelitis Optica Spectrum Disorder (NMOSD) who received the treatment for four or more years. These data are published in the Multiple Sclerosis Journal. The data demonstrate that long-term UPLIZNA use is associated with a reduced risk of NMOSD attacks – possibly due to the depth and extent of B-cell depletion with repeated doses. Key study findings include the following: A total of 18 attacks occurred in 13 people, with an annualized attack rate of 0.052 attacks per person year. The small number of total attacks decreased significantly after the first year of treatment with UPLIZNA. 67% of attacks occurred within the first year (12 attacks). 92% of patients were attack-free in subsequent years (two attacks each

For further details see:

Horizon reports new analysis from late-stage Uplinza study for NMOSD in medical journal